1 / 10

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifyin

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. For more details : http://goo.gl/WVUmG0

Shubhangi
Download Presentation

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifyin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceuticals & Healthcare  Market Research Reports Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation For More Information Visit : www.aarkstore.com

  2. Summary Large and Innovative Pipeline The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. GBI Research analysis revealed a high degree of innovation in this indication, with 46% of the pipeline being first-in-class products, acting on over 40 first-in-class molecular targets. In addition, the pipeline is characterized by the strong presence of therapies that target multiple components implicated in the amyloid cascade, several molecular targets of which are known to trigger familial AD. Given that the currently approved therapies for AD are limited to acetylcholinesterase inhibitors and glutamate receptor antagonists, the pipeline offers a broad range of treatment options that may possess disease-modifying properties. However, evaluation of the Preclinical and clinical evidence for their therapeutic potential reveals that the novelty of the molecular target is not sufficient to effectively reduce the rate of AD progression in human patients. For More Information Visit : www.aarkstore.com

  3. Scope The report covers and includes - - A brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms- The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline- A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target- Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets- Assessment of the licensing and co-development deal landscape for AD therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products For More Information Visit : www.aarkstore.com

  4. Reasons to buy The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to - - Understand the focal shifts in molecular targets in the AD pipeline- Understand the distribution of pipeline programs by phase of development, molecule type and molecular target- Access a scientific and clinical analysis of first-in-class developmental programs for AD, benchmarked against non-first-in-class targets- Access a list of the first-in-class therapies potentially open to deal-making opportunities For More Information Visit : www.aarkstore.com

  5. Table of Content 1.1 List of Tables 31.2 List of Figures 32 Executive Summary 43 The Case for Innovation 64 Clinical and Commercial Landscape 115 Assessment of Product Pipeline Innovation 216 Signaling Network, Genetics and Innovation Alignment 357 First-in-Class Target Evaluation 398 Deals and Strategic Consolidations 759 First-In-Class Molecules not Involved in Licensing or Co-development Deals 8610 Appendix 89 For More Information Visit : www.aarkstore.com

  6. List of Tables Table 1: Mini-Mental State Exam, 2005 15Table 2: Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 1984 16 For More Information Visit : www.aarkstore.com

  7. List Of Figures Figure 1: Innovation Trends in Product Approvals, 1987–2012 6Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Product post Marketing Approval, 2006–2013 8Figure 3: Sales Performance of Central Nervous System First-in-Class and Non-First-in-Class Products post Marketing Approval, 2006–2013 8Figure 4: Alzheimer’s Disease, Global, Developmental Pipeline 22Figure 5: Alzheimer’s Disease, Global, Established and First-in-Class Pipeline 25Figure 6: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 1, 2014 27Figure 7: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 2, 2014 28Figure 8: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 3, 2014 29Figure 9: Alzheimer’s Disease, Global, Established Developmental Pipeline Part 4, 2014 30Figure 10: Alzheimer’s Disease, Global, First-in-Class Developmental Pipeline Part 1, 2014 32 • Browse full report Or Sample Request @ • http://www.aarkstore.com/pharmaceuticals-healthcare/105777/frontier-pharma-alzheimers-disease-identifying-and-commercializing-first-in-class-innovation For More Information Visit : www.aarkstore.com

  8. Related Reports • 2015 Global Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape • 2015 European Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape • 2015 France Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape • 2015 Germany Infectious Disease Molecular Diagnostics Market: Country Forecasts, Supplier Shares, Emerging Technologies, Competitive Landscape • Global Healthcare IT Integration Market 2015-2019 • Dialysis Catheters Market in the US 2015-2019 • Global Immunodiagnostics Market 2015-2019 • Pharmaceuticals & Healthcare Market Research Reports For More Information Visit : www.aarkstore.com

  9. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

  10. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com

More Related